Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pancho Villa's Short Analysis File -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (47)	10/10/1998 1:19:00 AM
From: Mad2	Respond to of 287

Pancho, Synm caught my eye as I'm familiar with the oil gas and chemical industry. In many regards it shows potential as a fantastic short. Looking through some of the public documents it appears synm is a reverse merger with shl, where shl provided the cash and synm provided the "product". What has me puzzled if I understand this thing correctly, is before the merger shl had 31% of synm. With the merger that happened a short time ago shl gives synm $50mil and the orignal shl shareholders end up with 36% of the new synm. In effect old shl shareholders gave $50 mil. Seems a bit lopsided. On one hand I'm thinking "what does old shl mgmt know" as seemingly their action implies quite a bit of value in synm. Yet this also has the appearance of a very poorly timed scheme (reverse merge a loosing idea of how to get rich quick into a public shell pump and dump). Admitedly I haven't looked too deep into this yet, thus maybe the obvious is yet to be uncovered, however I'm still worried about this $50mil which smart people don't toss out. Was shl just stupid? BTW the latest filing is very interesting!!! You have been following this for a while, what's your take??

To: Pancho Villa who wrote (47)	10/15/1998 7:32:00 PM
From: TRIIBoy	Respond to of 287

IMNX's earnings and conference call came and went and I did not here what I thought I would here. 1)No talk of financing concerns for next year, has $140 million in cash 2)No talk of lowering estimates 3)and no talk of delaying FDA approval I covered today and recommend you do the same or protect yourself with calls.